779 results on '"Dillner, Joakim"'
Search Results
2. WHO International Standards for antibodies to HPV6 HPV11 HPV31 HPV33 HPV45 HPV52 and HPV58
3. Lack of detectable HPV18 antibodies in 14% of quadrivalent vaccinees in a longitudinal cohort study
4. The Swedish Cervical Screening Cohort
5. Concomitant human papillomavirus (HPV) vaccination and screening for elimination of HPV and cervical cancer
6. Human papillomavirus negative high grade cervical lesions and cancers: Suggested guidance for HPV testing quality assurance
7. Assessing household lifestyle exposures from consumer purchases, the My Purchases cohort
8. First international proficiency study on human papillomavirus testing in cervical cancer screening
9. IPVS policy statement on HPV nucleic acid testing guidance for those utilising/considering HPV as primary precancer screening: Quality assurance and quality control issues
10. Evaluation of co-testing with cytology and human papillomavirus testing in cervical screening
11. Impact of cervical screening by human papillomavirus genotype: Population-based estimations
12. Overtreatment rate after immediate local excision of suspected cervical intraepithelial neoplasia: A prospective cohort study
13. Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial
14. Comparing one dose of HPV vaccine in girls aged 9–14 years in Tanzania (DoRIS) with one dose of HPV vaccine in historical cohorts: an immunobridging analysis of a randomised controlled trial
15. Improving human papillomavirus (HPV) testing in the cervical cancer elimination era: The 2021 HPV LabNet international proficiency study
16. Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study
17. Quadrivalent HPV (4vHPV) vaccine immunogenicity and safety in women using immunosuppressive drugs due to solid organ transplant.
18. Low methylation marker levels among human papillomavirus‐vaccinated women with cervical high‐grade squamous intraepithelial lesions.
19. Continuous Global Improvement of Human Papillomavirus (HPV) Genotyping Services: The 2022 and 2023 HPV LabNet International Proficiency Studies.
20. The WID-CIN test identifies women with, and at risk of, cervical intraepithelial neoplasia grade 3 and invasive cervical cancer
21. DNA methylation-based detection and prediction of cervical intraepithelial neoplasia grade 3 and invasive cervical cancer with the WID™-qCIN test
22. The WID-BC-index identifies women with primary poor prognostic breast cancer based on DNA methylation in cervical samples
23. Differences in risk for SARS-CoV-2 infection among healthcare workers
24. The 2019 HPV Labnet international proficiency study: Need of global Human Papillomavirus Proficiency Testing
25. 2020 list of human papillomavirus assays suitable for primary cervical cancer screening
26. Misclassifications in human papillomavirus databases
27. Determinants of Human Papillomavirus Vaccine Uptake by Adult Women Attending Cervical Cancer Screening in 9 European Countries
28. Nationwide registry‐based trial of risk‐stratified cervical screening.
29. Elimination of HPV–associated oropharyngeal cancers in Nordic countries
30. A dose-reduction HPV vaccine immunobridging trial of two HPV vaccines among adolescent girls in Tanzania (the DoRIS trial) – Study protocol for a randomised controlled trial
31. Head-to-head comparison of two human papillomavirus vaccines for efficacy against cervical intraepithelial neoplasia grade 3 and adenocarcinoma in situ--population-based follow-up of two cluster-randomized trials.
32. Criteria for second generation comparator tests in validation of novel HPV DNA tests for use in cervical cancer screening.
33. Seroepidemiological assessment of the spread of SARS-CoV-2 among 25 and 28 year-old adult women in Finland between March 2020-June 2022.
34. Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four nordic countries
35. Deep sequencing detects human papillomavirus (HPV) in cervical cancers negative for HPV by PCR
36. Impact of HPV vaccination on cervical screening performance: a population-based cohort study
37. Antibodies to SARS-CoV-2 and risk of past or future sick leave
38. Multianalyte serology in home-sampled blood enables an unbiased assessment of the immune response against SARS-CoV-2
39. Comparison of DNA and RNA sequencing of total nucleic acids from human cervix for metagenomics
40. Evaluation of 11 SARS-CoV-2 antibody tests by using samples from patients with defined IgG antibody titers
41. Age-specific HPV type distribution in high-grade cervical disease in screened and unvaccinated women
42. Scientific approaches toward improving cervical cancer elimination strategies.
43. Divergent effects of switching from cytology to HPV-based screening in the Nordic countries.
44. Human Papillomavirus Serology Among Women Living With HIV : Type-Specific Seroprevalence, Seroconversion, and Risk of Cervical Reinfection
45. Seroprevalences of Antibodies to 11 Human Papillomavirus (HPV) Types Mark Cumulative HPV Exposure
46. The Valgent4 protocol: Robust analytical and clinical validation of 11 HPV assays with genotyping on cervical samples collected in SurePath medium
47. Time for a European initiative for research to prevent cancer: A manifesto for Cancer Prevention Europe (CPE)
48. Viremia preceding multiple sclerosis: Two nested case-control studies
49. Continuing global improvement in human papillomavirus DNA genotyping services: The 2013 and 2014 HPV LabNet international proficiency studies
50. HPV Vaccination and the Risk of Invasive Cervical Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.